Acetylcholinesterase Inhibition of Diversely Functionalized Quinolinones for Alzheimer's Disease Therapy

Affiliation auteurs!!!! Error affiliation !!!!
TitreAcetylcholinesterase Inhibition of Diversely Functionalized Quinolinones for Alzheimer's Disease Therapy
Type de publicationJournal Article
Year of Publication2020
AuteursBautista-Aguilera OM, Ismaili L, Chioua M, Andrys R, Schmidt M, Bzonek P, Martinez-Grau Mangeles, Beadle CD, Vetman T, Lopez-Munoz F, Iriepa I, Refouvelet B, Musilek K, Marco-Contelles J
JournalINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume21
Pagination3913
Date PublishedJUN
Type of ArticleArticle
Mots-clésAlzheimer's disease, ChE/MAO inhibition, contilisant, dihydroquinolinones, docking, quinolinones, synthesis
Résumé

In this communication, we report the synthesis and cholinesterase (ChE)/monoamine oxidase (MAO) inhibition of 19 quinolinones (QN1-19) and 13 dihydroquinolinones (DQN1-13) designed as potential multitarget small molecules (MSM) for Alzheimer's disease therapy. Contrary to our expectations, none of them showed significant human recombinant MAO inhibition, but compounds QN8, QN9, and DQN7 displayed promising human recombinant acetylcholinesterase (hrAChE) and butyrylcholinesterase (hrBuChE) inhibition. In particular, molecule QN8 was found to be a potent and quite selective non-competitive inhibitor of hrAChE (IC50 = 0.29 mu M), with K-i value in nanomolar range (79 nM). Pertinent docking analysis confirmed this result, suggesting that this ligand is an interesting hit for further investigation.

DOI10.3390/ijms21113913